TSMHT
CERE

Thurston Springer Miller Herd & Titak’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,107
Closed -$127K – 1579
2024
Q2 		$127K Buy
+3,107
New +$129K 0.04% 371

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's CERE Position: Q3 2024 in Review

Thurston Springer Miller Herd & Titak sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 3,107 shares — an estimated $127K sold.

Thurston Springer Miller Herd & Titak first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $127K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Thurston Springer Miller Herd & Titak reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 3,107 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $127K.
  • Thurston Springer Miller Herd & Titak first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $127K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2024, filed 11 Oct 2024.